C WorldWide Group Holding A S cut its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 3.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 284,588 shares of the biotechnology company’s stock after selling 10,587 shares during the period. C WorldWide Group Holding A S owned 0.10% of Exelixis worth $6,896,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. First Quadrant L P CA bought a new position in shares of Exelixis in the second quarter worth about $144,000. Fisher Asset Management LLC bought a new position in shares of Exelixis in the third quarter worth about $213,000. Wetherby Asset Management Inc. bought a new position in shares of Exelixis in the second quarter worth about $218,000. Caxton Associates LP bought a new position in shares of Exelixis in the second quarter worth about $227,000. Finally, Raymond James Financial Services Advisors Inc. bought a new position in shares of Exelixis in the third quarter worth about $236,000. Institutional investors and hedge funds own 79.03% of the company’s stock.
A number of equities analysts have recently commented on EXEL shares. TheStreet upgraded Exelixis from a “c” rating to a “b-” rating in a research note on Monday, August 7th. Piper Jaffray Companies restated a “buy” rating and set a $29.00 price target on shares of Exelixis in a research note on Thursday, August 3rd. BidaskClub lowered Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 14th. Needham & Company LLC restated a “buy” rating and set a $30.00 price target (up from $28.00) on shares of Exelixis in a research note on Tuesday, September 12th. Finally, Zacks Investment Research upgraded Exelixis from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a research note on Tuesday, October 10th. Six equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $31.38.
TRADEMARK VIOLATION WARNING: This article was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.chaffeybreeze.com/2017/11/12/exelixis-inc-exel-stake-lowered-by-c-worldwide-group-holding-a-s.html.
Exelixis, Inc. (NASDAQ EXEL) traded up $0.10 during mid-day trading on Friday, hitting $25.85. The stock had a trading volume of 2,050,200 shares, compared to its average volume of 5,064,375. Exelixis, Inc. has a 52 week low of $14.22 and a 52 week high of $32.50. The company has a market cap of $7,647.80, a price-to-earnings ratio of 50.69, a P/E/G ratio of 1.25 and a beta of 1.89.
Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.18. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. The company had revenue of $152.50 million for the quarter, compared to analyst estimates of $104.91 million. During the same period in the prior year, the company posted ($0.04) EPS. The company’s revenue was up 145.2% compared to the same quarter last year. equities analysts expect that Exelixis, Inc. will post 0.45 earnings per share for the current year.
In other news, insider Michael Morrissey sold 300,000 shares of the company’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $26.90, for a total value of $8,070,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Stelios Papadopoulos sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $25.40, for a total value of $254,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 970,152 shares of company stock worth $25,923,457. Corporate insiders own 5.10% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.